AboutLifeTree
About Lifetree - Who We Are Our Philosophy Executive Management Team: Alice A. Jackson, R.N. Lynn R. Webster, MD, FACPM, FASAM Matthew Iverson Sean Kotrady, CCRC, CCRP Neuroscience Research Team: Miroslav "Misha" Bačkonja, MD Mark A. Johnston, MD N. Lee Smith, MD Daniel B. Vine, MD Mary Jane Norman, MD Dennis Thoen, MD Debra F. Hobbins, DNP, APRN, LSAC, CARN-AP
ClinicalResearch
THERAPEUTIC EXPERTISE Clinical Research Abstracts Abuse Liability Analgesia Pain Model Development Lifetree Center for Neuroscience Research Phase 1 Research Sleep Medicine Ophthalmology
Clinical TrialManagement
Clinical Trial Management Data Management Services Interactive Voice Response System Medical and Safety Management Medical Writing Biostatistics and Analysis Services Drug Development Services
PressRoom
Press Releases & News Media Coverage Research Articles Calendar of Events
ContactLifeTree
Contact Lifetree Employment Opportunities For Study Participants For Biopharmaceutical and Device Clients Physicians: Become a Lifetree Investigator
VolunteerFor a Study
Volunteer - Screening Survey Current Research Studies Clinical Research Studies: Alzheimer's Clinical Trial Bunion Removal Chlamydia Home Testing Kit Chronic Pain Chronic Pain from Post-Herpetic Neuralgia Depression Clinical Trial Diabetic Peripheral Neuropathy Drug Abuse Study - Recreational use of Prescription Medications Gonorrhea Home Testing Kit Healthy Males and Females Healthy Seniors Hepatitis C Clinical Trial High Blood Pressure Hypertension Low Back Pain Mild Dementia Migraine Headaches Multiple Sclerosis Opioid Induced Constipation Osteoarthritis of the Hip and or Knee Schizophrenia Clinical Trial Sciatica Suboxone Wisdom Teeth Removal

News & Press Releases

< back to News & Press Releases

Date: Mar 21 2011

Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule

Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company’s next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies. Read the full release.

Lynn R. Webster, MD, Primary Investigator for the Phase 1 Study and Medical Director of Lifetree Clinical Research, said, "New pain medicines are desperately needed that are as powerful as opioids, but without the usual serious risks such as respiratory depression and disabling sedation."